Perspective highlights the complexity of disclosing APOE dementia risk to families, suggesting the need for integrated genetic-exposome communication approaches.
As genetic and biomarker-based dementia risk assessments become more widely used, the challenge is not only estimating risk, but returning it responsibly. Discussing my mother’s APOE genotype with her showed me how differently dementia risk can appear in a dataset, a family conversation, and lived experience. That lesson now shapes my work on integrated genetic–exposome risk assessments and return-of-results approaches.
No takes yet. Share an insight, caveat, or question.
Shea J. Andrews (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: